442908-10-3

Basic information

• Product Name: Vipadenant
• Synonyms: BIIB 014;Vipadenant;Vipadenant(BIIB 014);3-[(4-Amino-3-methylphenyl)methyl]-7-(2-furanyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-amine;CEB 4520;V 2006;VER 11135;VER-A 00049
• CAS NO: 442908-10-3
• Molecular Formula: C₁₆H₁₅N₇O
• Molecular Weight: 321.3366
• Product Categories: Inhibitors
• Mol File: 442908-10-3.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Vipadenant(CAS DataBase Reference)
• NIST Chemistry Reference: Vipadenant(442908-10-3)
• EPA Substance Registry System: Vipadenant(442908-10-3)

Safety Data

• Hazardous Substances Data: 442908-10-3(Hazardous Substances Data)

Usage

Description

Vipadenant, also known as BIIB014, is a potent, selective, and orally available adenosine A2A receptor antagonist currently under development for the treatment of Parkinson's disease. It has successfully completed phase I clinical studies and has shown potential as a promising adjunctive therapy reagent for cancer treatment, with the ability to disrupt an immunosuppressive mechanism of tumor protection and enhance the efficacy of immunotherapies for certain cancers when used in combination with other drugs.

Uses

Used in Parkinson's Disease Treatment:
Vipadenant is used as a potent, selective, and orally available adenosine A2A receptor antagonist for the treatment of Parkinson's disease. It demonstrates strong oral activity in commonly used models of Parkinson's disease and has shown excellent preclinical pharmacokinetics, successfully completing phase I clinical studies.
Used in Cancer Treatment:
Vipadenant is used as a potential adjunctive therapy reagent for cancer treatment. It has the ability to disrupt an immunosuppressive mechanism of tumor protection, generating improved efficacy for immunotherapies of certain cancers when used in combination with other drugs.

References

http://www.medkoo.com/products/8047 Shook, B. C., and P. F. Jackson. "Adenosine A(2A) Receptor Antagonists and Parkinson's Disease. " Acs Chemical Neuroscience2.10(2011):555-67. Brooks, D. J., et al. "An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers." Clinical Neuropharmacology 33.2(2010):55. http://www.vernalis.com/nce-pipeline/oncology/v2006

Upstream product

• 442906-78-7 7-(2-furyl)-1H-[1,2,3]triazolo[4,5-d]pyrimidine-5-amine 
• 141281-38-1 4-(bromomethyl)-2-methyl-1-nitrobenzene 
• 442908-07-8 7-(furan-2-yl)-3-(3-methyl-4-nitrobenzyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine 

Relevant articles and documents

Antagonists of the human A2A adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines

Antagonism of the human A2A receptor has been implicated as a point of therapeutic intervention in the alleviation of the symptoms associated with Parkinson's disease. This is thought to occur, at least in part, by increasing the sensitivity of the dopaminergic neurons to the residual, depleted levels of striatal dopamine. We herein describe a novel series of functionalized triazolo[4,5-d]pyrimidine derivatives that display functional antagonism of the A2A receptor. Optimization of these compounds has resulted in improvements in potency, selectivity, and the pharmacokinetic properties of key derivatives. These efforts have led to the discovery of 60 (V2006/BIIB014), which demonstrates strong oral activity in commonly used models of Parkinson's disease. Furthermore, this derivative has shown excellent preclinical pharmacokinetics and has successfully completed phase I clinical studies. This compound is presently undergoing further clinical evaluation in collaboration with Biogen Idec.